【Golden Biotechnology】Announcement of the Board of Directors' Approval of the Financial Report for Q1 2026
NQ Score
0/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).